These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 8750152)

  • 21. Phase II trial of interleukin 2, interferon alpha, and 5-fluorouracil in metastatic renal cell cancer: a cytokine working group study.
    Dutcher JP; Logan T; Gordon M; Sosman J; Weiss G; Margolin K; Plasse T; Mier J; Lotze M; Clark J; Atkins M
    Clin Cancer Res; 2000 Sep; 6(9):3442-50. PubMed ID: 10999727
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical outcome of combined immunotherapy with interferon-alpha and low-dose interleukine-2 for Japanese patients with metastatic renal cell carcinoma.
    Miyake H; Kurahashi T; Takenaka A; Inoue TA; Fujisawa M
    Urol Oncol; 2009; 27(6):598-603. PubMed ID: 18818106
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A multi-institutional phase II trial of a novel inpatient schedule of continuous interleukin-2 with interferon alpha-2b in advanced renal cell carcinoma: major durable responses in a less highly selected patient population.
    Clark JI; Kuzel TM; Lestingi TM; Fisher SG; Sorokin P; Martone B; Viola M; Sosman JA
    Ann Oncol; 2002 Apr; 13(4):606-13. PubMed ID: 12056712
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Phase I trial of sorafenib in combination with IFN alpha-2a in patients with unresectable and/or metastatic renal cell carcinoma or malignant melanoma.
    Escudier B; Lassau N; Angevin E; Soria JC; Chami L; Lamuraglia M; Zafarana E; Landreau V; Schwartz B; Brendel E; Armand JP; Robert C
    Clin Cancer Res; 2007 Mar; 13(6):1801-9. PubMed ID: 17363536
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Outpatient treatment with subcutaneous histamine dihydrochloride in combination with interleukin-2 and interferon-alpha in patients with metastatic renal cell carcinoma: results of an open single-armed multicentre phase II study.
    Donskov F; von der Maase H; Henriksson R; Stiemer U; Wersäll P; Nellemann H; Hellstrand K; Engman K; Naredi P
    Ann Oncol; 2002 Mar; 13(3):441-9. PubMed ID: 11996477
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Correlation of clinical and immunological parameters of metastatic renal cell carcinoma patients undergoing therapy with interleukin 2, interferon-alpha and retinoic acid.
    Elsässer-Beile U; Kölble N; Grussenmeyer T; Wetterauer U; Schultze-Seemann W
    Anticancer Res; 1998; 18(3B):1883-90. PubMed ID: 9677439
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cytoreductive radiofrequency ablation in patients with metastatic renal cell carcinoma (RCC) with small primary tumours treated with sunitinib or interferon-α.
    Tsimafeyeu I; Zart JS; Chung B
    BJU Int; 2013 Jul; 112(1):32-8. PubMed ID: 23746142
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Feasibility of prolonged use of interferon-alpha in metastatic kidney carcinoma: a phase II study.
    Kankuri M; Pelliniemi TT; Pyrhönen S; Nikkanen V; Helenius H; Salminen E
    Cancer; 2001 Aug; 92(4):761-7. PubMed ID: 11550145
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immunochemotherapy with interleukin-2, interferon-alpha and 5-fluorouracil for progressive metastatic renal cell carcinoma: a multicenter phase II study. Dutch Immunotherapy Working Party.
    van Herpen CM; Jansen RL; Kruit WH; Hoekman K; Groenewegen G; Osanto S; De Mulder PH
    Br J Cancer; 2000 Feb; 82(4):772-6. PubMed ID: 10732744
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Our experience with interferon alpha: renal cell carcinoma.
    Merimsky O; Chaitchik S
    Mol Biother; 1992 Sep; 4(3):130-4. PubMed ID: 1445666
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The prognostic significance of immune changes in patients with renal cancer, melanoma and colorectal cancer, treated with interferon alpha 2b.
    Tsavaris N; Baxevanis C; Kosmidis P; Papamichael M
    Cancer Immunol Immunother; 1996 Oct; 43(2):94-102. PubMed ID: 8954143
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Phase-II trial of combination treatment of interferon-α, cimetidine, cyclooxygenase-2 inhibitor and renin-angiotensin-system inhibitor (I-CCA therapy) for advanced renal cell carcinoma.
    Tatokoro M; Fujii Y; Kawakami S; Saito K; Koga F; Matsuoka Y; Iimura Y; Masuda H; Kihara K
    Cancer Sci; 2011 Jan; 102(1):137-43. PubMed ID: 20973869
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Phase I study of subcutaneously administered interleukin-2 in combination with interferon alfa-2a in patients with advanced cancer.
    Gause BL; Sznol M; Kopp WC; Janik JE; Smith JW; Steis RG; Urba WJ; Sharfman W; Fenton RG; Creekmore SP; Holmlund J; Conlon KC; VanderMolen LA; Longo DL
    J Clin Oncol; 1996 Aug; 14(8):2234-41. PubMed ID: 8708712
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pembrolizumab Plus Pegylated Interferon alfa-2b or Ipilimumab for Advanced Melanoma or Renal Cell Carcinoma: Dose-Finding Results from the Phase Ib KEYNOTE-029 Study.
    Atkins MB; Hodi FS; Thompson JA; McDermott DF; Hwu WJ; Lawrence DP; Dawson NA; Wong DJ; Bhatia S; James M; Jain L; Robey S; Shu X; Homet Moreno B; Perini RF; Choueiri TK; Ribas A
    Clin Cancer Res; 2018 Apr; 24(8):1805-1815. PubMed ID: 29358500
    [No Abstract]   [Full Text] [Related]  

  • 35. Recombinant alpha-interferon and vinblastine in metastatic renal cell carcinoma: efficacy of low doses.
    Cetto GL; Franceschi T; Turrina G; Chiarion-Sileni V; Capelli MC; Bellini A; Paccagnella A; Bassetto MA; Molino AM; de Sandre G
    Semin Surg Oncol; 1988; 4(3):184-90. PubMed ID: 3055162
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phase II trial of sorafenib plus interferon alfa-2b as first- or second-line therapy in patients with metastatic renal cell cancer.
    Gollob JA; Rathmell WK; Richmond TM; Marino CB; Miller EK; Grigson G; Watkins C; Gu L; Peterson BL; Wright JJ
    J Clin Oncol; 2007 Aug; 25(22):3288-95. PubMed ID: 17664476
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A comparison of 2 modes of administration of recombinant interleukin-2: continuous intravenous infusion alone versus subcutaneous administration plus interferon alpha in patients with advanced renal cell carcinoma.
    Palmer PA; Atzpodien J; Philip T; Negrier S; Kirchner H; Von der Maase H; Geertsen P; Evers P; Loriaux E; Oskam R
    Cancer Biother; 1993; 8(2):123-36. PubMed ID: 7804353
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Can the CD4+/CD8+ ratio predict the outcome of interferon-alpha therapy for renal cell carcinoma?
    Hernberg M; Muhonen T; Pyrhönen S
    Ann Oncol; 1997 Jan; 8(1):71-7. PubMed ID: 9093710
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A combination of subcutaneous recombinant interleukin-2 and recombinant interferon-alpha in the treatment of advanced renal cell carcinoma or melanoma.
    Vuoristo M; Jantunen I; Pyrhönen S; Muhonen T; Kellokumpu-Lehtinen P
    Eur J Cancer; 1994; 30A(4):530-2. PubMed ID: 8018415
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Treatment of metastatic renal cell carcinoma with coumarin (1,2-benzopyrone) and cimetidine: a pilot study.
    Marshall ME; Mendelsohn L; Butler K; Riley L; Cantrell J; Wiseman C; Taylor R; Macdonald JS
    J Clin Oncol; 1987 Jun; 5(6):862-6. PubMed ID: 3585442
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.